- $18.55m
- -$50.77m
- $6.44m
FibroGen Inc expected to post a loss of 30 cents a share - Earnings Preview
FibroGen Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Fibrogen Inc Enters Lease Termination Agreement For Premises Located At 409 Illinois Street
Brief: Fibrogen Initiates Restructuring Plan After Negative Pamrevlumab Clinical Trial Data
FibroGen Inc reports results for the quarter ended in June - Earnings Summary
Brief: FibroGen Q2 EPS USD -0.16
FibroGen Inc expected to post a loss of 32 cents a share - Earnings Preview
FibroGen falls as its cancer drug fails in two studies
Brief: Fibrogen Announces Topline Results From Two Late-Stage Pamrevlumab Pancreatic Cancer Studies
Brief: Fibrogen Files For Mixed Shelf Of Up To $300 Million
Brief: FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals
Brief: FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165
Brief: FibroGen Announces Presentation Of Positive Interim Data From The Phase 1B Study Of F-3246 In Combination With Enzalutamide In Patients With MCRPC
FibroGen Inc reports results for the quarter ended in March - Earnings Summary
Brief: FibroGen Q1 EPS USD -0.33
Brief: FibroGen Announces Topline Results From Phase 1 Monotherapy Study Of Fg-3246 In Patients With Metastatic Castration-Resistant Prostate Cancer
Brief: Fibrogen Appoints Deyaa Adib, M.D. As Chief Medical Officer
U.S. STOCKS ON THE MOVE-Cava, Bank of America, Fractyl Health
U.S. STOCKS ON THE MOVE-Kroger, Sezzle, Sealed Air Corp